Alvotech (OISE:ALVO) Pretax Margin %: 0.93% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OISE:ALVO Alvotech OISE:ALVO
55 GF Score
Price kr409.00
GF Value kr2,307.75
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Alvotech Pretax Margin %?

Alvotech OISE:ALVO -1.21% 55 Pretax Margin % is 0.93% as of Mar. 2026. GuruFocus rates OISE:ALVO with a GF Score™ of 55/100 and a GF Value™ of kr2,307.75 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 961 Drug Manufacturers companies, Alvotech ranks better than 51.4% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Alvotech's Pre-Tax Income for the three months ended in Mar. 2026 was kr124 Mil. Alvotech's Revenue for the three months ended in Mar. 2026 was kr13,275 Mil. Therefore, Alvotech's pretax margin for the quarter that ended in Mar. 2026 was 0.93%.

The historical rank and industry rank for Alvotech's Pretax Margin % or its related term are showing as below:

OISE:ALVO' s Pretax Margin % Range Over the Past 10 Years
Min: -712.04   Med: -437.99   Max: 23.25
Current: 7.85


OISE:ALVO's Pretax Margin % is ranked better than
51.4% of 961 companies
in the Drug Manufacturers industry
Industry Median: 7.28 vs OISE:ALVO: 7.85

Alvotech  (OISE:ALVO) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Alvotech Pretax Margin % Related Terms


Alvotech Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Alvotech's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alvotech Pretax Margin % Chart

Alvotech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Pretax Margin %
Get a 7-Day Free Trial -405.74 -664.40 -712.04 -44.43 23.25

Alvotech Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 70.37 5.37 -5.35 23.84 0.93

OISE:ALVO vs PAHC, COLL, XERS: Pretax Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Alvotech's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alvotech Pretax Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alvotech's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Alvotech's Pretax Margin % falls into.


OISE:ALVO
55GF Score
Alvotech OISE:ALVO
Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alvotech Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Alvotech's Pretax Margin for the fiscal year that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=17097.901/73524.058
=23.25 %

Alvotech's Pretax Margin for the quarter that ended in Mar. 2026 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=123.643/13275.364
=0.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of 0.93% mean?
Alvotech (OISE:ALVO) has a Pretax Margin % of 0.93% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Alvotech and its competitors. According to the industry distribution chart, Alvotech ranks #467 out of 961 companies in the Drug Manufacturers industry, placing it in the top 48.6%.
Is Alvotech's Pretax Margin % too high?
Alvotech's current Pretax Margin % is 0.93%. The Drug Manufacturers industry median Pretax Margin % is 7.28. Alvotech's value of 0.93% is 87.2% below this industry median. Based on the distribution chart, Alvotech ranks #467 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Alvotech has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Alvotech's Pretax Margin % compare to PAHC and COLL?
According to the Drug Manufacturers industry distribution chart, Alvotech ranks #467 out of 961 companies for Pretax Margin %. This puts Alvotech in the upper half of its industry. The industry median Pretax Margin % is 7.28. Alvotech's value of 0.93% is 87.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alvotech's current Pretax Margin % of 0.93% is 87.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Alvotech and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alvotech's current Pretax Margin % is 0.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alvotech stock overvalued right now?
Based on GuruFocus' analysis, Alvotech (OISE:ALVO) is currently considered Possible Value Trap. The stock's GF Value™ is kr2,307.75, compared to a current price of kr409.00 — trading 82.3% below its estimated fair value. The current Pretax Margin % is 0.93% and 87.2% below the Drug Manufacturers industry median of 7.28. Alvotech's overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Alvotech (OISE:ALVO), the current Pretax Margin % is 0.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alvotech (OISE:ALVO) Overvalued in 2026?

Based on GuruFocus' analysis, Alvotech stock appears to be undervalued. The current stock price of kr409.00 is trading 82.3% below its estimated GF Value™ of kr2,307.75. GuruFocus considers Alvotech to be Possible Value Trap.

Key valuation signals for OISE:ALVO:

  • Pretax Margin %: 0.93%
  • GF Value™: kr2,307.75 vs. price of kr409.00 (82.3% below fair value)
  • GF Score™: 55/100 with 7 warning signs
  • Industry Position: 87.2% below the Drug Manufacturers median (#467 of 961)

No single metric tells the full story. See the OISE:ALVO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alvotech Business Description

Other Exchanges ALVO:USAZ45:Germany
Address 9, rue de Bitbourg, Luxembourg, LUX, L-1273
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
55GF Score

Get the complete analysis for OISE:ALVO

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr409.00
Price
kr2,307.75
GF Value